

- Fingolimod is a sphingosine-1 phosphate receptor modulator for the treatment of relapsing multiple sclerosis (MS), and is currently approved in 13 Latin American countries.
- Differences in MS disease characteristics and socioeconomic factors exist in Latin American countries compared with other populations.
- Clinical and real-world experience of fingolimod is expanding in Latin American populations.
- Review of current fingolimod efficacy and safety data suggest outcomes in Latin America are similar to the rest of the world.

This summary slide represents the opinions of the authors. This review was funded by Novartis Pharma AG, Basel, Switzerland. Editorial support in the preparation of this manuscript was provided by Stephen Georgiou, PhD, and Sarah Griffiths, PhD, of Oxford PharmaGenesis Ltd, Oxford, UK, and was funded by Novartis Pharma AG. For a full list of acknowledgments and conflicts of interest for all authors of this article, please see the full text online. Copyright © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).